Naloxonum Hydrochloricum Wzf (Naloxone Hydrochloride)

Naloxone works by competitively binding to μ‑opioid receptors in the central nervous system without activating them. This displaces opioid molecules such as heroin, fentanyl, or morphine, blocking their effects and allowing normal respiratory and neurological function to return quickly after administration.

The specific dose of Naloxonum Hydrochloricum Wzf is determined by the prescribing clinician based on the patient’s condition, route of administration, and severity of opioid exposure. Healthcare providers follow established clinical guidelines and adjust dosing as needed during emergency care.

Safety data for naloxone in pregnancy and lactation are limited, but the drug is generally considered low risk because it does not cross the placenta in significant amounts and is minimally secreted in breast milk. Clinicians weigh potential benefits against any theoretical risks when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Naloxone is the most widely used opioid antagonist due to its rapid onset, short half‑life, and broad receptor affinity. Alternatives such as nalmefene have a longer duration of action but are less commonly used in acute overdose. Naloxone’s established safety profile and availability make it the first‑line choice in emergency settings.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Naloxonum Hydrochloricum Wzf is supplied as an injectable solution for intramuscular, intravenous, or subcutaneous injection. The route is selected by the treating clinician based on the clinical scenario, and the injection is performed using aseptic technique with appropriate needle size and volume.

Serious risks include acute opioid withdrawal, which can cause agitation, hypertension, tachycardia, and seizures, especially in patients with physical dependence. Rarely, cardiac arrhythmias, pulmonary edema, or severe hypertension may occur. Continuous monitoring after administration is essential to manage these potential complications.

Naloxone is contraindicated in individuals with a known hypersensitivity to naloxone or any component of the formulation. Caution is advised in patients with severe cardiovascular disease, as rapid reversal of opioid effects can precipitate hemodynamic instability. Clinical judgment should guide use in all cases.